首页> 外文期刊>American Journal of Pathology >Loss of Caveolin-3 Induces a Lactogenic Microenvironment that Is Protective Against Mammary Tumor Formation
【24h】

Loss of Caveolin-3 Induces a Lactogenic Microenvironment that Is Protective Against Mammary Tumor Formation

机译:Caveolin-3的损失诱导了乳原微环境,可以保护乳腺肿瘤的形成。

获取原文
获取原文并翻译 | 示例
           

摘要

Here, we show that functional loss of a single gene is sufficient to confer constitutive milk protein production and protection against mammary tumor formation. Caveolin-3 (Cav-3), a muscle-specific caveolin-related gene, is highly expressed in muscle cells. We demonstrate that Cav-3 is also expressed in myoepithelial cells within the mammary gland. To determine whether genetic ablation of Cav-3 expression affects adult mammary gland development, we studied the phenotype(s) of Cav-3–/–-null mice. Interestingly, Cav-3–/– virgin mammary glands developed lobulo-alveolar hyperplasia, akin to the changes normally observed during pregnancy and lactation. Genome-wide expression profiling revealed up-regulation of gene transcripts associated with pregnancy/lactation, mammary stem cells, and human breast cancers, consistent with a constitutive lactogenic phenotype. Expression levels of three key transcriptional regulators of lactation, namely Elf5, Stat5a, and c-Myc, were also significantly elevated. Experiments with pregnant mice directly showed that Cav-3–/– mice underwent precocious lactation. Finally, using orthotopic tumor cell implantation, we demonstrated that virgin Cav-3–/– mice were dramatically protected against mammary tumor formation. Thus, Cav-3–/– mice are a novel preclinical model to study the protective effects of a lactogenic microenvironment on mammary tumor onset and progression. Our current studies have broad implications for using the lactogenic microenvironment as a paradigm to discover new therapies for the prevention and/or treatment of human breast cancers.
机译:在这里,我们证明单个基因的功能丧失足以赋予乳成分蛋白质的生产和保护,从而防止乳腺肿瘤的形成。 Caveolin-3(Cav-3)是与肌肉相关的 caveolin相关基因,在肌肉细胞中高度表达。 我们证明了Cav-3在肌上皮细胞中也表达。乳腺中的 细胞。为了确定Cav-3表达的遗传 消融是否影响成年乳腺发育, 我们研究了Cav-3 – / – -空小鼠。 有趣的是,Cav-3 – / – 原始乳腺发生了 肺泡-肺泡增生,类似于通常观察到的变化< sup> 在怀孕和哺乳期间。全基因组表达谱 揭示了与妊娠/泌乳, 乳腺干细胞和人乳腺癌相关的基因转录本的上调,与 一致本构性产乳表型。哺乳期的三个 关键转录调节子,Elf5,Stat5a, 和c-Myc的表达水平也显着升高。对 妊娠小鼠的实验直接表明,Cav-3 – / – 小鼠 进行了早熟泌乳​​。最后,使用原位肿瘤 细胞植入,我们证明了原始的Cav-3 – /- 小鼠可以显着保护其免受乳腺肿瘤的形成。 > 因此,Cav-3 – // 小鼠是一种新型的临床前模型 ,用于研究生乳微环境 的保护作用。乳腺肿瘤的发生和发展。我们当前的研究 对于使用生乳微环境 作为范例来发现预防和/或 治疗人类乳腺癌的新方法具有广泛的意义。 。

著录项

  • 来源
    《American Journal of Pathology》 |2009年第2期|613-629|共17页
  • 作者单位

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania|and the Muscular and Neurodegenerative Disease Unit,University of Genoa and G. Gaslini Pediatric Institute, Genoa, Italy;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    and the Department of Pathology, Anatomy, and Cell Biology,Thomas Jefferson University, Philadelphia, Pennsylvania;

    and the Muscular and Neurodegenerative Disease Unit,University of Genoa and G. Gaslini Pediatric Institute, Genoa, Italy;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania;

    From the Departments of Cancer Biology and Medical Oncology,Thomas Jefferson University, Philadelphia, Pennsylvania|Kimmel Cancer Center, the Stem Cell Biology and Regenerative Medicine Center,Thomas Jefferson University, Philadelphia, Pennsylvania|and the Muscular and Neurodegenerative Disease Unit,University of Genoa and G. Gaslini Pediatric Institute, Genoa, Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号